Celcuity Inc. (CELC)

Market Cap	489.74M
Revenue (ttm)	n/a
Net Income (ttm)	-93.97M
Shares Out	37.13M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	199,915
Open	12.72
Previous Close	12.73
Day's Range	12.55 - 13.25
52-Week Range	11.51 - 22.19
Beta	0.75
Analysts	Strong Buy
Price Target	29.17 (+121.15%)
Earnings Date	Nov 14, 2024

About CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CELC
• Website: https://www.celcuity.com

Analyst Forecast

According to 6 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price forecast is $29.17, which is an increase of 121.15% from the latest price.

Price Target

$29.17

(121.15% upside)

Analyst Consensus: Strong Buy